Jan 21, 2013 | Compliance, Legal, and Malpractice, Digital Pathology, Laboratory News, Laboratory Pathology
Pathologists and clinical laboratory managers will likely learn next year whether Myriad’s gene patents will stand In the ongoing debate about gene patents, the nation’s highest legal authority is about to weigh in on the question. The Supreme Court has agreed to hear the Myriad Genetics patent case in the upcoming term. The case turns on whether human genes can be patented. Will Clinical Labs Need to Pay Royalties for Using Human Gene Patents? How the high court rules on this matter has...
Sep 28, 2011 | Digital Pathology, Laboratory News, Laboratory Pathology
Many in the clinical laboratory and pathology industry will hold their breath as Myriad seeks to derail gene patent challenge by attacking standing of sole remaining plaintiff There’s news regarding the widely-watched federal lawsuit that challenges the gene patents owned by Myriad Genetics (NASDAQ:MYGN). On September 13, a Federal Circuit panel denied the ACLU’s Petition for Rehearing in this case. Clinical laboratory managers and pathologists following this controversial lawsuit will be...
